| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
DSHS00884 targets the E6 oncoprotein of human papillomavirus (HPV). HPV E6 is a small protein that binds to the E6-associated protein (E6AP), a ubiquitin ligase, to form a complex that targets the tumor suppressor protein p53 for ubiquitination and proteasomal degradation. By eliminating p53, E6 prevents apoptosis and allows HPV-infected cells to proliferate, contributing to the development of cervical and other cancers. By inhibiting E6, DSHS00884 aims to disrupt this interaction, thereby stabilizing p53 and restoring its tumor suppressor function. Additionally, DSHS00884 also targets the replication machinery of coronaviruses, including SARS, MERS, and mouse hepatitis virus, though its specific target within the coronavirus life cycle is not detailed.
|
|---|---|
| ln Vitro |
DSHS00884, which has an IC50 of 2.5–25 μM, stabilizes p53 levels in HPV-positive cells by preventing E6-mediated p53 degradation[1].
DSHS00884 is a potent inhibitor of HPV E6, with an IC₅₀ of 10 μM. This in vitro activity is typically measured using biochemical assays that assess the interaction between E6 and E6AP or the E6-mediated degradation of p53. In cell-based assays, it has been shown to inhibit HPV E6 activity, leading to the accumulation of p53 and the induction of apoptosis in HPV-positive cancer cells. Furthermore, its activity against coronaviruses, including SARS, MERS, and mouse hepatitis virus, has been demonstrated in vitro, making it a broad-spectrum antiviral compound. The compound's ability to inhibit both an oncogenic viral protein and a family of clinically important coronaviruses is a remarkable feature. |
| ln Vivo |
While specific in vivo data for DSHS00884 is not detailed in the provided search results, its potent in vitro antiviral activity suggests it would be effective in vivo. Its activity against coronaviruses could be evaluated in animal models of SARS, MERS, or mouse hepatitis. Its HPV E6 inhibitory activity could be studied in mouse models of HPV-induced tumorigenesis. Such studies would be crucial for confirming its in vivo efficacy and for advancing its development as a potential therapeutic.
|
| Enzyme Assay |
The in vitro assay for HPV E6 inhibition typically measures the disruption of the E6-E6AP interaction or the restoration of p53 levels. For a biochemical assay, purified E6 and E6AP proteins are used. The interaction between them can be measured using techniques like ELISA or AlphaScreen. DSHS00884 is added at varying concentrations, and its ability to inhibit the binding is measured. Alternatively, a cell-based assay can be used. In this assay, HPV-positive cancer cells (e.g., HeLa or SiHa cells) are treated with DSHS00884, and the levels of p53 are measured by Western blot. An increase in p53 levels indicates successful E6 inhibition.
|
| Cell Assay |
In vitro cell-based assays for DSHS00884 evaluate its ability to inhibit HPV E6 activity and its antiviral activity against coronaviruses. For HPV, the primary assay is the measurement of p53 levels or the induction of apoptosis in HPV-positive cells as described above. For coronaviruses, the compound's antiviral activity is assessed by infecting susceptible cells (e.g., Vero E6 cells) with a coronavirus in the presence of varying concentrations of DSHS00884. After incubation, the extent of viral replication is measured by quantifying the viral RNA or by plaque assay. The reduction in viral replication in the presence of the compound is a measure of its antiviral activity.
|
| Animal Protocol |
In vivo animal studies for DSHS00884 would depend on the specific application. For its anti-coronavirus activity, a mouse model using mouse hepatitis virus (MHV) is a readily available and relevant system, as it is a coronavirus that naturally infects mice. Mice would be infected with MHV and treated with DSHS00884. Survival, weight loss, and viral loads in the lungs would be measured. For its anti-HPV activity, xenograft models using HPV-positive human cancer cells implanted in immunocompromised mice could be used. Tumor growth would be monitored, and the effect of DSHS00884 on tumor progression would be assessed.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for DSHS00884 is not available in the provided search results. Its molecular weight is 308.38. As a research compound, its ADME properties would be determined in preclinical studies.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for DSHS00884 is not publicly available. As a compound targeting viral proteins, its selectivity for the viral target over human proteins is a key determinant of its safety. It is classified as a research tool and is not intended for human use.
|
| References | |
| Additional Infomation |
DSHS00884 is a unique and interesting research compound due to its dual activity as an inhibitor of both HPV E6 and coronaviruses. This makes it a valuable tool for studying both HPV-associated cancers and coronavirus infections. The compound has not received FDA approval for any indication.
|
| Molecular Formula |
C12H12N4O2S2
|
|---|---|
| Molecular Weight |
308.379279136658
|
| Exact Mass |
308.04
|
| CAS # |
675104-49-1
|
| Related CAS # |
675104-49-1;SSYA10-001 HCl;
|
| PubChem CID |
2807230
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
436
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC=CC=1[N+](=O)[O-])CC1=NNC(N1CC=C)=S
|
| InChi Key |
VWFIHGWHMXSTAO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H12N4O2S2/c1-2-7-15-11(13-14-12(15)19)8-20-10-6-4-3-5-9(10)16(17)18/h2-6H,1,7-8H2,(H,14,19)
|
| Chemical Name |
3-[(2-nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
|
| Synonyms |
DSHS 00884 DSHS-00884 DSHS00884
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~810.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2428 mL | 16.2138 mL | 32.4275 mL | |
| 5 mM | 0.6486 mL | 3.2428 mL | 6.4855 mL | |
| 10 mM | 0.3243 mL | 1.6214 mL | 3.2428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
